Clasado has revealed that its award-winning prebiotic ingredient, Bimuno® GOS, has now surpassed 130 published scientific studies backing its efficacy.
The announcement further cements its position as the most comprehensively studied galactooligosaccharides (GOS) prebiotic ingredient available to health and nutrition formulators. Building on more than two decades of rigorous scientific research, Bimuno GOS is backed by evidence across multiple health areas, including gastrointestinal health, immune support, and cognitive and mental health and wellness, making it an ideal choice for formulators developing targeted health products.
This latest milestone reflects the depth of science behind Bimuno GOS, reinforcing its position as one of the most researched GOS for adult nutrition. A recent addition includes research published in Metabolites, which demonstrated that Bimuno GOS delivers a proven bifidogenic effect at ultra-low doses from just 380mg of active GOS daily, opening new possibilities for capsule and tablet formulations where space is at a premium.
Consumer interest in gut health continues to accelerate across global markets, with McKinsey studies reporting that more than 80% of consumers in China, the UK and the US, recognise its importance. What’s more, over 50% anticipate making it a key health priority in the coming years. As a result, the demand for scientifically substantiated ingredients has never been greater. Bimuno GOS’s extensive evidence base gives formulators a trusted foundation for products that can meet both long-term consumer health priorities and evolving market trends.
Dr Lucien Harthoorn, R&D Director at Clasado, commented: “Reaching 130 publications represents another significant milestone in our scientific journey. What makes this achievement particularly special is the diversity of our latest research, with further studies due to be published this year. From demonstrating efficacy at capsule-compatible doses to proving benefits for elite athletes, we’re continually expanding what’s possible with Bimuno GOS. These studies show how our ingredient can meet the evolving needs of formulators across different product formats and health categories.”
Per Rehné, CEO at Clasado, added: “This milestone reflects a strong period of progress for Clasado, including Bimuno GOS surpassing 100 available health claims across multiple global markets. Our commitment to advancing prebiotic science through rigorous research continues to set us apart very clearly in the marketplace. With over 130 publications now supporting Bimuno GOS, including more than 25 clinical trials, we’re providing our formulation partners with unparalleled scientific substantiation for their product development and marketing claims.”
Bimuno GOS selectively nourishes beneficial bacteria in the gut microbiome, supporting gut health and overall wellbeing through microbiome modulation. The ingredient’s proven efficacy, combined with excellent stability and formulation flexibility, makes it the prebiotic of choice for brands seeking science-backed solutions for today’s health-conscious consumers.
To learn more about Bimuno GOS click here.
